{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T19:13:28Z","timestamp":1785266008451,"version":"3.55.0"},"reference-count":80,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:00:00Z","timestamp":1771977600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:00:00Z","timestamp":1774569600000},"content-version":"vor","delay-in-days":30,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001111","name":"Cancer Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001111","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001170","name":"Cancer Council Western Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001170","id-type":"DOI","asserted-by":"publisher"}]},{"name":"iCare Dust Diseases Care"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-41431-4","type":"journal-article","created":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:47:39Z","timestamp":1771980459000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Mesothelioma location influences the tumour microenvironment and immune checkpoint therapy response in preclinical models"],"prefix":"10.1038","volume":"16","author":[{"given":"M. Lizeth","family":"Orozco Morales","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally M.","family":"Lansley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wee Loong","family":"Chin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlin M.","family":"Tilsed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Principe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Connull","family":"Leslie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Breana J.","family":"Vitali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francois X.","family":"Rwandamuriye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"de Jong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel","family":"Kidman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachael M.","family":"Zemek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine A.","family":"Rinaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timo","family":"Lassmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Bosco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y. C. Gary","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Lake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Chee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. Joost","family":"Lesterhuis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,25]]},"reference":[{"key":"41431_CR1","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ijheh.2017.09.013","volume":"221","author":"JW Cherrie","year":"2018","unstructured":"Cherrie, J. W., McElvenny, D. & Blyth, K. G. Estimating past inhalation exposure to asbestos: A tool for risk attribution and disease screening. Int. J. Hyg. Environ. Health. 221, 27\u201332 (2018).","journal-title":"Int. J. Hyg. Environ. Health"},{"key":"41431_CR2","first-page":"1053","volume":"7","author":"N Zhang","year":"2017","unstructured":"Zhang, N., Fu, N., Peng, S. & Luo, X. Malignant mesothelioma of the tunica vaginalis testis: A case report and literature review. Mol. Clin. Oncol. 7, 1053\u20131056 (2017).","journal-title":"Mol. Clin. Oncol."},{"key":"41431_CR3","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S1607-551X(09)70044-0","volume":"25","author":"JL Chen","year":"2009","unstructured":"Chen, J. L. & Hsu, Y. H. Malignant mesothelioma of the tunica vaginalis testis: A case report and literature review. Kaohsiung J. Med. Sci. 25, 77\u201381 (2009).","journal-title":"Kaohsiung J. Med. Sci."},{"key":"41431_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fonc.2022.950371","volume":"12","author":"S Shao","year":"2022","unstructured":"Shao, S. et al. Survival analysis and development of a prognostic nomogram for patients with malignant mesothelioma in different anatomic sites. Front. Oncol. 12, 1\u201315 (2022).","journal-title":"Front. Oncol."},{"key":"41431_CR5","doi-asserted-by":"crossref","unstructured":"Ullah, A. et al. Incidence, survival analysis and future perspective of primary peritoneal mesothelioma (PPM): A population-based study from SEER database. Cancers. 14 (2022).","DOI":"10.3390\/cancers14040942"},{"key":"41431_CR6","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1016\/S1470-2045(20)30462-9","volume":"21","author":"AK Nowak","year":"2020","unstructured":"Nowak, A. K. et al. Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): A multicentre, single-arm, phase 2 trial with a safety run-in. Lancet Oncol. 21, 1213\u20131223 (2020).","journal-title":"Lancet Oncol."},{"key":"41431_CR7","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","volume":"397","author":"P Baas","year":"2021","unstructured":"Baas, P. et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): A multicentre, randomised, open-label, phase 3 trial. Lancet 397, 375\u2013386 (2021).","journal-title":"Lancet"},{"key":"41431_CR8","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/j.jtho.2023.02.003","volume":"18","author":"MC Piccirillo","year":"2023","unstructured":"Piccirillo, M. C. et al. Brief Report: Canadian Cancer Trials Group IND.227: A phase 2 randomized study of pembrolizumab in patients with advanced malignant pleural mesothelioma (NCT02784171). J. Thorac. Oncol. 18, 813\u2013819 (2023).","journal-title":"J. Thorac. Oncol."},{"key":"41431_CR9","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1158\/2767-9764.CRC-23-0524","volume":"4","author":"X Ma","year":"2024","unstructured":"Ma, X. et al. Spatial landscape of malignant pleural and peritoneal mesothelioma tumor immune microenvironments. Cancer Res. Commun. 4, 2133\u20132146 (2024).","journal-title":"Cancer Res. Commun."},{"key":"41431_CR10","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1136\/thoraxjnl-2020-216602","volume":"76","author":"M Shamseddin","year":"2021","unstructured":"Shamseddin, M. et al. Use of preclinical models for malignant pleural mesothelioma. Thorax 76, 1154\u20131162 (2021).","journal-title":"Thorax"},{"key":"41431_CR11","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1158\/1535-7163.MCT-07-0579","volume":"7","author":"NR Miselis","year":"2008","unstructured":"Miselis, N. R., Wu, Z. J., Van Rooijen, N. & Kane, A. B. Targeting tumor-associated macrophages in an orthotopic murine model of diffuse malignant mesothelioma. Mol. Cancer Ther. 7, 788\u2013799 (2008).","journal-title":"Mol. Cancer Ther."},{"key":"41431_CR12","doi-asserted-by":"publisher","first-page":"3290","DOI":"10.1158\/0008-5472.CAN-11-3481","volume":"72","author":"S Jube","year":"2012","unstructured":"Jube, S. et al. Cancer cell secretion of the DAMP protein HMGB1 supports progression in malignant mesothelioma. Cancer Res. 72, 3290\u20133301 (2012).","journal-title":"Cancer Res."},{"key":"41431_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/srep22850","volume":"6","author":"R Mezzapelle","year":"2016","unstructured":"Mezzapelle, R. et al. Human malignant mesothelioma is recapitulated in immunocompetent BALB\/c mice injected with murine AB cells. Sci. Rep. 6, 1\u201312 (2016).","journal-title":"Sci. Rep."},{"key":"41431_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2407-6-130","volume":"6","author":"D Martarelli","year":"2006","unstructured":"Martarelli, D. et al. Characterization of human malignant mesothelioma cell lines orthotopically implanted in the pleural cavity of immunodeficient mice for their ability to grow and form metastasis. BMC Cancer. 6, 1\u20137 (2006).","journal-title":"BMC Cancer"},{"key":"41431_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers12082136","volume":"12","author":"E Digifico","year":"2020","unstructured":"Digifico, E. et al. Optimization of a luciferase-expressing non-invasive intrapleural model of malignant mesothelioma in immunocompetent mice. Cancers (Basel). 12, 1\u201314 (2020).","journal-title":"Cancers (Basel)"},{"key":"41431_CR16","doi-asserted-by":"publisher","first-page":"103571","DOI":"10.1016\/j.isci.2021.103571","volume":"25","author":"ML Orozco Morales","year":"2022","unstructured":"Orozco Morales, M. L. et al. PPAR\u03b1 and PPAR\u03b3 activation is associated with pleural mesothelioma invasion but therapeutic inhibition is ineffective. iScience 25, 103571 (2022).","journal-title":"iScience"},{"key":"41431_CR17","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/bjc.2016.412","volume":"116","author":"D Anastasiou","year":"2017","unstructured":"Anastasiou, D. Tumour microenvironment factors shaping the cancer metabolism landscape. Br. J. Cancer. 116, 277\u2013286 (2017).","journal-title":"Br. J. Cancer"},{"key":"41431_CR18","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.ccell.2022.05.016","volume":"40","author":"WW Ho","year":"2022","unstructured":"Ho, W. W., Pittet, M. J., Fukumura, D. & Jain, R. K. The local microenvironment matters in preclinical basic and translational studies of cancer immunology and immunotherapy. Cancer Cell. 40, 701\u2013702 (2022).","journal-title":"Cancer Cell."},{"key":"41431_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 1\u201321 (2014).","journal-title":"Genome Biol."},{"key":"41431_CR20","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/ng1180","volume":"34","author":"VK Mootha","year":"2003","unstructured":"Mootha, V. K. et al. PGC-1\u03b1-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat. Genet. 34, 267\u2013273 (2003).","journal-title":"Nat. Genet."},{"key":"41431_CR21","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian, A. et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. U S A. 102, 15545\u201315550 (2005).","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"41431_CR22","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1093\/bioinformatics\/btt703","volume":"30","author":"A Kr\u00e4mer","year":"2014","unstructured":"Kr\u00e4mer, A., Green, J., Pollard, J. & Tugendreich, S. Causal analysis approaches in ingenuity pathway analysis. Bioinformatics 30, 523\u2013530 (2014).","journal-title":"Bioinformatics"},{"key":"41431_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-022-29311-7","volume":"13","author":"KD Prummel","year":"2022","unstructured":"Prummel, K. D. et al. Hand2 delineates mesothelium progenitors and is reactivated in mesothelioma. Nat. Commun. 13, 1\u201321 (2022).","journal-title":"Nat. Commun."},{"key":"41431_CR24","doi-asserted-by":"publisher","first-page":"2645","DOI":"10.1038\/s41388-018-0153-z","volume":"37","author":"H Rehrauer","year":"2018","unstructured":"Rehrauer, H. et al. How asbestos drives the tissue towards tumors: YAP activation, macrophage and mesothelial precursor recruitment, RNA editing, and somatic mutations. Oncogene 37, 2645\u20132659 (2018).","journal-title":"Oncogene"},{"key":"41431_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/jcmm.18330","volume":"28","author":"KA Papavassiliou","year":"2024","unstructured":"Papavassiliou, K. A., Sofianidi, A. A. & Papavassiliou, A. G. YAP\/TAZ-TEAD signalling axis: A new therapeutic target in malignant pleural mesothelioma. J. Cell. Mol. Med. 28, 1\u20136 (2024).","journal-title":"J. Cell. Mol. Med."},{"key":"41431_CR26","doi-asserted-by":"publisher","first-page":"2663","DOI":"10.1111\/jcmm.13182","volume":"21","author":"WQ Zhang","year":"2017","unstructured":"Zhang, W. Q. et al. Targeting YAP in malignant pleural mesothelioma. J. Cell. Mol. Med. 21, 2663\u20132676 (2017).","journal-title":"J. Cell. Mol. Med."},{"key":"41431_CR27","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1080\/15384047.2016.1145850","volume":"17","author":"AC Borczuk","year":"2016","unstructured":"Borczuk, A. C. et al. Genome-wide analysis of abdominal and pleural malignant mesothelioma with DNA arrays reveals both common and distinct regions of copy number alteration. Cancer Biol. Ther. 17, 328\u2013335 (2016).","journal-title":"Cancer Biol. Ther."},{"key":"41431_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1126\/scitranslmed.aav7816","volume":"11","author":"RM Zemek","year":"2019","unstructured":"Zemek, R. M. et al. Sensitization to immune checkpoint blockade through activation of a STAT1 \/ NK axis in the tumor microenvironment. Sci. Transl Med. 11, 1\u201314 (2019).","journal-title":"Sci. Transl Med."},{"key":"41431_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-022-32567-8","volume":"13","author":"RM Zemek","year":"2022","unstructured":"Zemek, R. M. et al. Temporally restricted activation of IFN\u03b2 signaling underlies response to immune checkpoint therapy in mice. Nat. Commun. 13, 1\u201316 (2022).","journal-title":"Nat. Commun."},{"key":"41431_CR30","doi-asserted-by":"crossref","unstructured":"Yoshihara, K. et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat. Commun. 4, (2013).","DOI":"10.1038\/ncomms3612"},{"key":"41431_CR31","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.21037\/tlcr-21-223","volume":"10","author":"Q Ma","year":"2021","unstructured":"Ma, Q. et al. A signature of estimate-stromal-immune score-based genes associated with the prognosis of lung adenocarcinoma. Transl Lung Cancer Res. 10, 1484\u20131500 (2021).","journal-title":"Transl Lung Cancer Res."},{"key":"41431_CR32","doi-asserted-by":"crossref","unstructured":"Yoshihara, K. et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat. Commun. 4, (2013).","DOI":"10.1038\/ncomms3612"},{"key":"41431_CR33","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.immuni.2018.03.023","volume":"48","author":"V Thorsson","year":"2018","unstructured":"Thorsson, V. et al. The immune landscape of cancer. Immunity 48, 812\u2013830e14 (2018).","journal-title":"Immunity"},{"key":"41431_CR34","doi-asserted-by":"crossref","unstructured":"Ujiie, H. et al. The tumoral and stromal immune microenvironment in malignant pleural mesothelioma: A comprehensive analysis reveals prognostic immune markers The tumoral and stromal immune microenvironment in malignant pleural mesothelioma : A comprehensive analysis rev. Oncoimmunology. 6, (2015).","DOI":"10.1080\/2162402X.2015.1009285"},{"key":"41431_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/stcltm\/szaf055","volume":"14","author":"A Jankelow","year":"2025","unstructured":"Jankelow, A., Almeida-Porada, G., Atala, A., Sawyer, S. W. & Porada, C. D. Recent advancements in tissue dissociation techniques for cell manufacturing single-cell analysis and downstream processing. Stem Cells Transl Med. 14, 1\u201313 (2025).","journal-title":"Stem Cells Transl Med."},{"key":"41431_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40425-015-0088-7","volume":"3","author":"A Cesano","year":"2015","unstructured":"Cesano, A. nCounter PanCancer Immune Profiling Panel (NanoString Technologies, Inc., Seattle, WA). J. Immunother Cancer. 3, 1\u20133 (2015).","journal-title":"J. Immunother Cancer"},{"key":"41431_CR37","unstructured":"Dennis, L. et al. Exploring Immuno-Oncology Using NCounter RNA: Protein Profiling Technology. (2015)."},{"key":"41431_CR38","unstructured":"Dennis, L., Kaufmann, S., Danaher, P., Bailey, C. & Beechem, J. Multiplexed Cancer Immune Response Analysis NCounter PanCancer Immune Profiling Panel for Gene Expression. (2019)."},{"key":"41431_CR39","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nmeth.3337","volume":"12","author":"AM Newman","year":"2015","unstructured":"Newman, A. M. et al. Robust enumeration of cell subsets from tissue expression profiles. Nat. Methods. 12, 453\u2013457 (2015).","journal-title":"Nat. Methods"},{"key":"41431_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1084\/jem.20211314","volume":"219","author":"Y Chen","year":"2022","unstructured":"Chen, Y., Zhang, J., Cui, W. & Silverstein, R. L. CD36, a signaling receptor and fatty acid transporter that regulates immune cell metabolism and fate. J. Exp. Med. 219, 1\u201315 (2022).","journal-title":"J. Exp. Med."},{"key":"41431_CR41","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","volume":"1","author":"A Liberzon","year":"2016","unstructured":"Liberzon, A. et al. The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell. Syst. 1, 417\u2013425 (2016).","journal-title":"Cell. Syst."},{"key":"41431_CR42","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1038\/s41568-024-00699-2","volume":"24","author":"RM Zemek","year":"2024","unstructured":"Zemek, R. M., Anagnostou, V., Pires da Silva, I., Long, G. V. & Lesterhuis, W. J. Exploiting temporal aspects of cancer immunotherapy. Nat. Rev. Cancer. 24, 480\u2013497 (2024).","journal-title":"Nat. Rev. Cancer"},{"key":"41431_CR43","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1038\/s43018-023-00534-x","volume":"4","author":"A Nabbi","year":"2023","unstructured":"Nabbi, A. et al. Multimodal immunogenomic biomarker analysis of tumors from pediatric patients enrolled to a phase 1\u20132 study of single-agent atezolizumab. Nat. Cancer. 4, 502\u2013515 (2023).","journal-title":"Nat. Cancer"},{"key":"41431_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/2162402X.2018.1494111","volume":"7","author":"VS Fear","year":"2018","unstructured":"Fear, V. S. et al. Combination immune checkpoint blockade as an effective therapy for mesothelioma. Oncoimmunology 7, 1\u201314 (2018).","journal-title":"Oncoimmunology"},{"key":"41431_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers13225664","volume":"13","author":"F Cersosimo","year":"2021","unstructured":"Cersosimo, F. et al. Mesothelioma malignancy and the microenvironment: Molecular mechanisms. Cancers (Basel). 13, 1\u201320 (2021).","journal-title":"Cancers (Basel)"},{"key":"41431_CR46","doi-asserted-by":"publisher","first-page":"101435","DOI":"10.1016\/j.gendis.2024.101435","volume":"12","author":"Y Duan","year":"2025","unstructured":"Duan, Y. et al. Targeting MYC: Multidimensional regulation and therapeutic strategies in oncology. Genes Dis. 12, 101435 (2025).","journal-title":"Genes Dis."},{"key":"41431_CR47","first-page":"1","volume":"15","author":"L Wu","year":"2025","unstructured":"Wu, L., Wang, Z., Zia, A., Kelley, S. O. & de Perrot, M. Mesothelioma cell heterogeneity identified by single cell RNA sequencing. Sci. Rep. 15, 1\u201317 (2025).","journal-title":"Sci. Rep."},{"key":"41431_CR48","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1038\/s41416-020-01215-7","volume":"124","author":"MG White","year":"2021","unstructured":"White, M. G. & Eng, O. S. Response to Comment on Heterogeneity in PD-L1 expression in malignant peritoneal mesothelioma with systemic or intraperitoneal chemotherapy. Br. J. Cancer. 124, 1179\u20131180 (2021).","journal-title":"Br. J. Cancer"},{"key":"41431_CR49","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1038\/s41591-021-01541-0","volume":"27","author":"PM Forde","year":"2021","unstructured":"Forde, P. M. et al. Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: Survival, genomic and immunologic analyses from the phase 2 PrE0505 trial. Nat. Med. 27, 1910\u20131920 (2021).","journal-title":"Nat. Med."},{"key":"41431_CR50","first-page":"1","volume":"6","author":"WL Chin","year":"2025","unstructured":"Chin, W. L. et al. Coupling of response biomarkers between tumor and peripheral blood in patients undergoing chemoimmunotherapy. Cell. Rep. Med. 6, 1\u201318 (2025).","journal-title":"Cell. Rep. Med."},{"key":"41431_CR51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fonc.2024.1410322","volume":"14","author":"MF Reveneau","year":"2024","unstructured":"Reveneau, M. F. et al. Major response of a peritoneal mesothelioma to nivolumab and ipilimumab: A case report, molecular analysis and review of literature. Front. Oncol. 14, 1\u20139 (2024).","journal-title":"Front. Oncol."},{"key":"41431_CR52","doi-asserted-by":"publisher","first-page":"5296","DOI":"10.12998\/wjcc.v11.i22.5296","volume":"11","author":"XD Peng","year":"2023","unstructured":"Peng, X. D., You, Z. Y., He, L. X. & Deng, Q. Zimberelimab plus chemotherapy as the first-line treatment of malignant peritoneal mesothelioma: A case report and review of literature. World J. Clin. Cases. 11, 5296\u20135302 (2023).","journal-title":"World J. Clin. Cases"},{"key":"41431_CR53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3892\/ol.2025.15142","volume":"29","author":"C Xue","year":"2025","unstructured":"Xue, C. et al. Pembrolizumab as an effective treatment for diffuse malignant peritoneal mesothelioma with long-term survival: A case report and literature review. Oncol. Lett. 29, 1\u20139 (2025).","journal-title":"Oncol. Lett."},{"key":"41431_CR54","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1016\/S1470-2045(21)00471-X","volume":"22","author":"DA Fennell","year":"2021","unstructured":"Fennell, D. A. et al. Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): A multicentre, double-blind, randomised, phase 3 trial. Lancet Oncol. 22, 1530\u20131540 (2021).","journal-title":"Lancet Oncol."},{"issue":"3","key":"41431_CR55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1001\/jamanetworkopen.2023.2526","volume":"6","author":"ME Marmarelis","year":"2023","unstructured":"Marmarelis, M. E. et al. Clinical outcomes associated with pembrolizumab monotherapy among adults with diffuse malignant peritoneal mesothelioma. JAMA Netw. Open. 6 (3), 1\u20139 (2023).","journal-title":"JAMA Netw. Open."},{"key":"41431_CR56","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1038\/s41573-022-00520-5","volume":"21","author":"A Mantovani","year":"2022","unstructured":"Mantovani, A., Allavena, P., Marchesi, F. & Garlanda, C. Macrophages as tools and targets in cancer therapy. Nat. Rev. Drug Discov. 21, 799\u2013820 (2022).","journal-title":"Nat. Rev. Drug Discov"},{"key":"41431_CR57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-019-0760-3","volume":"12","author":"Y Lin","year":"2019","unstructured":"Lin, Y., Xu, J. & Lan, H. Tumor-associated macrophages in tumor metastasis: Biological roles and clinical therapeutic applications. J. Hematol. Oncol. 12, 1\u201316 (2019).","journal-title":"J. Hematol. Oncol."},{"key":"41431_CR58","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1016\/j.jtho.2016.06.022","volume":"11","author":"AL Ch\u00e9n\u00e9","year":"2016","unstructured":"Ch\u00e9n\u00e9, A. L. et al. Pleural effusions from patients with mesothelioma induce recruitment of monocytes and their differentiation into M2 macrophages. J. Thorac. Oncol. 11, 1765\u20131773 (2016).","journal-title":"J. Thorac. Oncol."},{"key":"41431_CR59","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fphar.2023.1254317","volume":"14","author":"L Yu","year":"2023","unstructured":"Yu, L., Gao, Y., Aaron, N. & Qiang, L. A glimpse of the connection between PPAR\u03b3 and macrophage. Front. Pharmacol. 14, 1\u20139 (2023).","journal-title":"Front. Pharmacol."},{"key":"41431_CR60","first-page":"1","volume":"8","author":"S Chen","year":"2023","unstructured":"Chen, S. et al. Macrophages in immunoregulation and therapeutics. Signal. Transduct. Target. Ther. 8, 1\u201335 (2023).","journal-title":"Signal. Transduct. Target. Ther."},{"key":"41431_CR61","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1084\/jem.20200851","volume":"218","author":"WH Fridman","year":"2021","unstructured":"Fridman, W. H. et al. B cells and cancer: To B or not to B? J. Exp. Med. 218, 1\u201311 (2021).","journal-title":"J. Exp. Med."},{"key":"41431_CR62","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s10555-010-9223-6","volume":"29","author":"DG DeNardo","year":"2010","unstructured":"DeNardo, D. G., Andreu, P. & Coussens, L. M. Interactions between lymphocytes and myeloid cells regulate pro-versus anti-tumor immunity. Cancer Metastasis Rev. 29, 309\u2013316 (2010).","journal-title":"Cancer Metastasis Rev."},{"key":"41431_CR63","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s44276-025-00146-1","volume":"3","author":"A Hegoburu","year":"2025","unstructured":"Hegoburu, A., Amer, M., Frizelle, F. & Purcell, R. B cells and tertiary lymphoid structures in cancer therapy response. BJC Rep. 3, 1\u20137 (2025).","journal-title":"BJC Rep."},{"key":"41431_CR64","first-page":"1","volume":"0","author":"X Li","year":"2025","unstructured":"Li, X. et al. Tertiary lymphoid structures: Allies of cancer immunotherapy. Immunology 0, 1\u201326 (2025).","journal-title":"Immunology"},{"key":"41431_CR65","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1126\/sciadv.adu0292","volume":"12","author":"B Priem","year":"2026","unstructured":"Priem, B. et al. Systemically inducing trained immunity overcomes solid tumors\u2019 immunosuppressive microenvironment. Sci. Adv. 12, 1\u201316 (2026).","journal-title":"Sci. Adv."},{"key":"41431_CR66","doi-asserted-by":"publisher","first-page":"2483","DOI":"10.1093\/annonc\/mdv387","volume":"26","author":"AK Nowak","year":"2015","unstructured":"Nowak, A. K. et al. A phase 1b clinical trial of the CD40-activating antibody CP-870,893 in combination with cisplatin and pemetrexed in malignant pleural mesothelioma. Ann. Oncol. 26, 2483\u20132490 (2015).","journal-title":"Ann. Oncol."},{"key":"41431_CR67","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1084\/jem.20171440","volume":"215","author":"S Hoves","year":"2018","unstructured":"Hoves, S. et al. Rapid activation of tumor-associated macrophages boosts preexisting tumor immunity. J. Exp. Med. 215, 859\u2013876 (2018).","journal-title":"J. Exp. Med."},{"key":"41431_CR68","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.tig.2025.08.002","volume":"42","author":"MF Grinwald","year":"2025","unstructured":"Grinwald, M. F., Saintilnord, W. N. & Wang, T. Unmasked: transposable elements as drivers and targets in cancer. Trends Genet. 42, 30\u201345 (2025).","journal-title":"Trends Genet."},{"key":"41431_CR69","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1002\/ijc.2910520609","volume":"52","author":"MR Davis","year":"1992","unstructured":"Davis, M. R., Manning, L. S., Whitaker, D., Garlepp, M. J. & Robinson, B. W. S. Establishment of a murine model of malignant mesothelioma. Int. J. Cancer. 52, 881\u2013886 (1992).","journal-title":"Int. J. Cancer"},{"key":"41431_CR70","doi-asserted-by":"publisher","first-page":"5051","DOI":"10.4049\/jimmunol.171.10.5051","volume":"171","author":"C Jackaman","year":"2003","unstructured":"Jackaman, C. et al. IL-2 intratumoral immunotherapy enhances CD8\u2009+\u2009T cells that mediate destruction of tumor cells and tumor-associated vasculature: a novel mechanism for IL-2. J. Immunol. 171, 5051\u20135063 (2003).","journal-title":"J. Immunol."},{"key":"41431_CR71","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-019-51317-3","volume":"9","author":"VS Fear","year":"2019","unstructured":"Fear, V. S. et al. Neo-antigen specific T cell responses indicate the presence of metastases before imaging. Sci. Rep. 9, 1\u201310 (2019).","journal-title":"Sci. Rep."},{"key":"41431_CR72","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1165\/rcmb.2014-0017OC","volume":"53","author":"SM Lansley","year":"2015","unstructured":"Lansley, S. M., Cheah, H. M., Della Vergiliana, J. F. V., Chakera, A. & Lee, Y. C. G. Tissue plasminogen activator potently stimulates pleural effusion via a monocyte chemotactic protein-1-dependent mechanism. Am. J. Respir Cell. Mol. Biol. 53, 105\u2013112 (2015).","journal-title":"Am. J. Respir Cell. Mol. Biol."},{"key":"41431_CR73","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/nbt.3519","volume":"34","author":"NL Bray","year":"2016","unstructured":"Bray, N. L., Pimentel, H., Melsted, P. & Pachter, L. Near-optimal probabilistic RNA-seq quantification. Nat. Biotechnol. 34, 525\u2013527 (2016).","journal-title":"Nat. Biotechnol."},{"key":"41431_CR74","doi-asserted-by":"publisher","first-page":"D916","DOI":"10.1093\/nar\/gkaa1087","volume":"49","author":"A Frankish","year":"2021","unstructured":"Frankish, A. et al. Gencode 2021. Nucleic Acids Res. 49, D916\u2013D923 (2021).","journal-title":"Nucleic Acids Res."},{"key":"41431_CR75","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 1\u201321 (2014).","journal-title":"Genome Biol."},{"key":"41431_CR76","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fgene.2022.791920","volume":"13","author":"L Fu","year":"2022","unstructured":"Fu, L., Wang, Y., Li, T., Yang, S. & Hu, Y. Q. A novel hierarchical clustering approach for joint analysis of multiple phenotypes uncovers obesity variants based on ARIC. Front. Genet. 13, 1\u201313 (2022).","journal-title":"Front. Genet."},{"key":"41431_CR77","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nmeth.3337","volume":"12","author":"AM Newman","year":"2015","unstructured":"Newman, A. M. et al. Robust enumeration of cell subsets from tissue expression profiles. Nat. Methods. 12, 453\u2013457 (2015).","journal-title":"Nat. Methods"},{"key":"41431_CR78","first-page":"1","volume":"7","author":"Z Chen","year":"2017","unstructured":"Chen, Z. et al. Inference of immune cell composition on the expression profiles of mouse tissue. Sci. Rep. 7, 1\u201311 (2017).","journal-title":"Sci. Rep."},{"key":"41431_CR79","doi-asserted-by":"publisher","unstructured":"Frazee, C. et al. Flexible isoform-level differential expression analysis with Ballgown. bioRxiv 0\u201313 https:\/\/doi.org\/10.1101\/003665 (2014).","DOI":"10.1101\/003665"},{"key":"41431_CR80","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/2162402X.2018.1494111","volume":"7","author":"VS Fear","year":"2018","unstructured":"Fear, V. S. et al. Combination immune checkpoint blockade as an effective therapy for mesothelioma. Oncoimmunology 7, 1\u201314 (2018).","journal-title":"Oncoimmunology"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-41431-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-41431-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-41431-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T11:01:55Z","timestamp":1774609315000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-41431-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,25]]},"references-count":80,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["41431"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-41431-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-8016867\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,25]]},"assertion":[{"value":"3 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10473"}}